Compare Taskus Inc (TASK) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Taskus Inc vs Viatris Inc — how do they compare? Taskus Inc trades at $5.86 (market cap $532.07M), while Viatris Inc trades at $17.15 (market cap $19.79B). The key difference: Viatris Inc is far larger — about 37.2× Taskus Inc's market cap, and Viatris Inc pays a 2.83% dividend while Taskus Inc pays none. Which is the better fit depends on your goals.
| TASK | VTRS | |
|---|---|---|
Market Cap | $532.07M | $19.79B |
Sector | Technology | Health |
52-Week High | $18.21 | $17.39 |
52-Week Low | $4.57 | $8.74 |
Enterprise Value | $927.77M | $32.00B |
Dividend Yield | — | 2.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TaskUs (TASK) trades at $5.81, down 0.34% on the day, with a bullish technical signal from moving averages but bearish oscillators. The company reported Q1 2026 earnings of $0.35 per share, missing estimates, after beating in the prior two quarters. Revenue reached $1.18 billion in 2025 with net income of $102.28 million, showing strong profitability. Analysts maintain a consensus buy rating with a $9.50 price target, suggesting significant upside potential.
The stock appears undervalued with a P/E of 5.16 and P/S of 0.45, supported by robust ROE of 26.52%. Risks include recent earnings miss and competitive pressures in digital services. Positive cash flow and debt reduction trends provide fundamental strength, but investor sentiment is mixed amid technical overbought signals.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Taskus Inc
TaskUs Inc is a provider of outsourced digital services and next-generation customer experience to innovative and disruptive technology companies. It serves clients in the fastest-growing sectors, including social media, e-commerce, gaming, streaming media, food delivery and ridesharing, HiTech, FinTech and HealthTech.
Read more on TASK →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
